Trelegy Ellipta

Asthma, Chronic Obstructive Pulmonary Disease, Seasonal Allergies + 1 more

Treatment

3 FDA approvals

20 Active Studies for Trelegy Ellipta

Treatment for

Asthma

What is Trelegy Ellipta

Fluticasone furoateThe Generic name of this drug

Treatment SummaryFluticasone furoate is a synthetic steroid medication used for treating inflammation. It is available as an inhaler and nasal spray and was first approved by the FDA in 2007.

Veramystis the brand name

image of different drug pills on a surface

Trelegy Ellipta Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Veramyst

Fluticasone furoate

2007

Approved as Treatment by the FDA

Fluticasone furoate, otherwise known as Veramyst, is approved by the FDA for 3 uses which include Asthma and Asthma .

Asthma

Used to treat Asthma in combination with Umeclidinium

Asthma

Used to treat Asthma in combination with Umeclidinium

Chronic Obstructive Pulmonary Disease

Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Umeclidinium

Effectiveness

How Trelegy Ellipta Affects PatientsFluticasone furoate has been shown to activate certain hormones and inhibit certain chemicals when tested in a laboratory setting. This drug has been found to reduce eosinophilia (a type of white blood cell) in the lungs of rats.

How Trelegy Ellipta works in the bodyFluticasone furoate works to reduce inflammation in the body. In tests, it has been shown to activate certain receptors in the body, as well as inhibit certain proteins. This prevents the body from producing substances that cause inflammation.

When to interrupt dosage

The prescribed dosage of Trelegy Ellipta is contingent upon the recognized condition, including Sinusitis, Sinusitis and Perennial Allergic Rhinitis (PAR). The amount of dosage is contingent upon the technique of delivery (e.g. Respiratory (inhalation) or Powder - Respiratory (inhalation)) outlined in the table beneath.

Condition

Dosage

Administration

Asthma

, 0.0275 mg, 0.1 mg, 0.2 mg, 0.0275 mg/spray, 0.05 mg, 0.092 mg, 0.184 mg, 0.1 mg/pump actuation, 0.2 mg/pump actuation, 0.0275 mg/pump actuation

Nasal, , Spray, metered, Spray, metered - Nasal, Powder, Powder - Respiratory (inhalation), Respiratory (inhalation), Intrasinal, Spray, suspension - Intrasinal, Powder, metered - Respiratory (inhalation), Powder, metered, Spray, suspension

Seasonal Allergies

, 0.0275 mg, 0.1 mg, 0.2 mg, 0.0275 mg/spray, 0.05 mg, 0.092 mg, 0.184 mg, 0.1 mg/pump actuation, 0.2 mg/pump actuation, 0.0275 mg/pump actuation

Perennial Allergy

, 0.0275 mg, 0.1 mg, 0.2 mg, 0.0275 mg/spray, 0.05 mg, 0.092 mg, 0.184 mg, 0.1 mg/pump actuation, 0.2 mg/pump actuation, 0.0275 mg/pump actuation

Chronic Obstructive Pulmonary Disease

, 0.0275 mg, 0.1 mg, 0.2 mg, 0.0275 mg/spray, 0.05 mg, 0.092 mg, 0.184 mg, 0.1 mg/pump actuation, 0.2 mg/pump actuation, 0.0275 mg/pump actuation

Warnings

Trelegy Ellipta has seven contraindications and should not be combined with the conditions provided in the following table.Trelegy Ellipta Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Status Asthmaticus

Do Not Combine

Status Asthmaticus

Do Not Combine

Pulse Frequency

Do Not Combine

Asthma

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluticasone Furoate may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Fluticasone Furoate may interact with Pulse Frequency

There are 20 known major drug interactions with Trelegy Ellipta.

Common Trelegy Ellipta Drug Interactions

Drug Name

Risk Level

Description

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Fluticasone furoate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Fluticasone furoate.

Acteoside

Major

The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Acteoside.

Aldesleukin

Major

The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluticasone furoate.

Trelegy Ellipta Toxicity & Overdose RiskTaking fluticasone furoate through the nose may lead to a decrease in the body's adrenal hormones or a longer than usual heartbeat. No dose adjustments are needed for those with kidney problems, but those with liver problems should use caution. Fluticasone has not been linked to cancer, mutations, or infertility. There is not much data on how it affects pregnant women or babies, though animal studies have shown that it can cause birth defects and low adrenal hormones in offspring. Children should be given the lowest dose possible and monitored for any growth delays. Elderly patients should also be monitored closely as they may need a different

Trelegy Ellipta Novel Uses: Which Conditions Have a Clinical Trial Featuring Trelegy Ellipta?

252 active clinical trials are examining the potential of Trelegy Ellipta in alleviating Sinusitis, Chronic Obstructive Pulmonary Disease (COPD) and Asthma.

Condition

Clinical Trials

Trial Phases

Asthma

92 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Seasonal Allergies

0 Actively Recruiting

Perennial Allergy

0 Actively Recruiting

Trelegy Ellipta Reviews: What are patients saying about Trelegy Ellipta?

5Patient Review

5/7/2022

Trelegy Ellipta for Bronchospasm Prevention with COPD

Trelegy has been a godsend for my stage 4 COPD. It's prevented exacerbations and flare-ups since I started using it four months ago. The only side effect I've noticed is some gunk around my eyes in the morning, but that's nothing compared to how well this medication works. Be sure to rinse your mouth out after use or you'll get thrush, though. Overall, managing COPD is a lot easier with Trelegy.

5Patient Review

4/7/2022

Trelegy Ellipta for Bronchospasm Prevention with COPD

I had been taking Spiriva, but it wasn't very effective. Trelegy has given me my life back. Recently I was on vacation and did a lot of walking without needing a wheelchair or stops to catch my breath. It's wonderful. Thanks GSK!

5Patient Review

2/28/2021

Trelegy Ellipta for Controller Medication for Asthma

I was prescribed Trelegy after Symbicort wasn't helping. This was all after Covid Double Pneumonia

5Patient Review

11/26/2021

Trelegy Ellipta for Bronchospasm Prevention with COPD

Trelegy has been an absolute godsend. I never smoked, but severe asthma starting when I was four years old led to lung damage as the years went by. Trelegy is the best thing that's ever happened to me in terms of managing my condition.

4.7Patient Review

7/2/2022

Trelegy Ellipta for Controller Medication for Asthma

Advair was my maintenance medication for many years, but it gradually lost its effectiveness. However, the first day after using Trelegy, I found that I didn't need to use my rescue inhaler as often. I'm very pleased with this product and haven't experienced any negative side effects.

3.3Patient Review

1/6/2022

Trelegy Ellipta for Bronchospasm Prevention with COPD

Though this treatment helped my copd for a little while, I found that after 6 or 8 hours I was right back to feeling short of breath and wheezing. This is supposed to be a once-a-day medication, but I had to use my nebulizer and emergency inhaler the rest of the day.

3Patient Review

1/30/2022

Trelegy Ellipta for Controller Medication for Asthma

I unfortunately experienced some intense side effects after taking this medication. Bladder pain and uncontrolled urination were the main two issues I had.

2.3Patient Review

8/15/2022

Trelegy Ellipta for Prevention of Bronchospasms with Emphysema

I find that all breathing aids provide me with temporary relief at best, and often leave me feeling more congested than before. At $472, this is an ineffective and overpriced medication.

2Patient Review

7/22/2022

Trelegy Ellipta for Prevention of Bronchospasms with Emphysema

Within two days of taking this medication, my left parotid gland (responsible for producing saliva) began to swell. I'm not sure if the powder from the drug caused a blockage that led to the swelling.

1.7Patient Review

9/29/2022

Trelegy Ellipta for Bronchospasm Prevention with COPD

I got sick after using this treatment for only eleven days out of the fourteen day sample. I had the flu for two weeks and then developed thrush. I still don't feel back to normal even a month later.

Patient Q&A Section about trelegy ellipta

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does Trelegy cost per month?

"62.3% of TRELEGY prescriptions fall under $50 per month, with the average prescription costing $178 per month. The amount an individual pays is based on the coverage provided by their prescription drug benefit plan."

Answered by AI

What are the side effects of trilogy?

"If you have a fungal infection in your mouth or throat, you may be at risk for developing pneumonia. If you have a weakened immune system, you may be more likely to get infections. If you have reduced adrenal function, you may experience sudden breathing problems after inhaling TRELEGY. If you experience serious allergic reactions, you should seek medical attention immediately."

Answered by AI

What is Trelegy Ellipta used for?

"TRELEGY is a prescription medicine that is used to treat COPD and asthma in adults. The only approved strength for COPD is TRELEGY 100/62.5/25 mcg. TRELEGY is not used to relieve sudden breathing problems and won't replace a rescue inhaler."

Answered by AI

Is Trelegy Ellipta a steroid inhaler?

"The long term use of inhaled steroids can lead to weight gain by causing an increase in the production of cortisol. Cortisol is a hormone which can effect your metabolism and too much of it can lead to weight gain."

Answered by AI

Clinical Trials for Trelegy Ellipta

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions

Have you considered Trelegy Ellipta clinical trials? We made a collection of clinical trials featuring Trelegy Ellipta, we think they might fit your search criteria.

Have you considered Trelegy Ellipta clinical trials? We made a collection of clinical trials featuring Trelegy Ellipta, we think they might fit your search criteria.